|
See related Reyataz cap information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
DKSH |
|
Contents |
Atazanavir sulfate |
|
Indications |
Treatment of HIV-1 infection in combination w/ other antiretroviral agents. |
|
Dosage |
400 mg once daily; or Reyataz 300 mg + ritonavir 100 mg. W/ efavirenz: Reyataz 300 mg + ritonavir 100 mg + efavirenz 600 mg (all as a single daily dose w/ food). W/ didanosine: Didanosine (on an empty stomach) + Reyataz (w/ food). W/ tenofovir: Reyataz 300 mg + ritonavir 100 mg + tenofovir 300 mg (all as a single daily dose w/ food). |
|
Administration |
Should be taken with food |
|
Contraindications |
Severe hepatic insufficiency. |
|
Special Precautions |
New-onset DM or exacerbation of preexisting DM, hyperglycaemia. Increased bleeding. Preexisting conduction system disease or co-administration w/ drugs that induce PR interval prolongation. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Nausea, jaundice, headache, lipodystrophy. Dizziness, insomnia, peripheral neuralgic symptoms, scleral icterus, abdominal pain, diarrhoea, vomiting, rash, asthenia, fatigue.
View ADR Monitoring Form |
|
Drug Interactions |
Rifampin, irinotecan, bepridil, ergot derivatives, cisapride, lovastatin, simvastatin, pimozide, indinavir, proton-pump inhibitors, midazolam, triazolam, St. John's wort.
View more drug interactions with Reyataz |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Reyataz capsule |
|
Reyataz 150 mg x 60's |
|
Reyataz 200 mg x 60's |
 |
|
Reyataz 300 mg x 30's |
 |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
DKSH |
|
|
|
|
|
